Key result
Shuangxinfang's bioactive compound Neocryptotanshinone demonstrated strong binding affinity to the hub target MAPK3 with a binding energy of -10.6 kcal/mol, suggesting a pivotal role in treating myocardial infarction with depression.
Why the study?
Patients with MI have a high incidence of depression, and while Shuangxinfang shows antidepressant and cardioprotective effects post-MI, its active compounds and underlying mechanisms remain unidentified.
Population
Control and model rats
Comparison
PCF solution lavage vs control
Design
Preclinical LC-MS/MS and bioinformatic prediction study
Follow-up
5 days
Authors
Loading...
Should not yet change practice in post-MI depression; hypothesis-generating for Neocryptotanshinone-MAPK3 targeting in cardio-neuroprotection.
Effect estimate: -10.6 kcal/mol
Network pharmacology and LC-MS/MS identified Neocryptotanshinone as a pivotal active ingredient in Shuangxinfang, potentially mediating cardio-neuroprotective effects post-MI via MAPK3.
Sun et al. (2025) studied Myocardial infarction with depression (n=18). Shuangxinfang (Psycho-cardiology Formula, PCF) vs. Distilled water was evaluated on Binding energy of Neocryptotanshinone to MAPK3 (-10.6 kcal/mol). Shuangxinfang's bioactive compound Neocryptotanshinone demonstrated strong binding affinity to the hub target MAPK3 with a binding energy of -10.6 kcal/mol, suggesting a pivotal role in treating myocardial infarction with depression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: